Regulatory approval

Published by the Health Service Executive. Approved

Pertuzumab/trastuzumab (Phesgo) and vinorelbine for the treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pertuzumab / Trastuzumab (Phesgo) - ODMS 2022-12-20; Vinorelbine - N/A

Citation

Pertuzumab/Trastuzumab (Phesgo) and Vinorelbine, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6421/798_v3_Pertuzumab_trastuzumab_Phesgo_vinorelbine.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2022-12-20	Health Service Executive	Indication approved for reimbursement.